CIK 0001357874
- Non-accelerated filer
- Smaller reporting company
PRECISION BIOSCIENCES INC
Sign in to watch- Ticker
- DTIL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- May 21
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 919-314-5512
- Business address
- 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
- Open-market buys, last 90 days
- $29,501
- in 3 filings
- Open-market sales, last 90 days
- $27,505
- in 1 filing, $28K under 10b5-1 plans
Net +$1,996. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 39 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-08 | KANE MATTHEW R. President and CEO | Sale | −9,736 | $9.00 | $88K | 1,941,246 |
| 2021-04-08 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 107,570 | ||
| 2021-03-18 | JANTZ DEREK Chief Scientific Officer | Option exercise | +21,514 | $0.04 | $861 | 3,990,909 |
| 2021-03-18 | JANTZ DEREK Chief Scientific Officer | Sale | −9,665 | $11.08 | $107K | 3,981,244 |
| 2021-03-18 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 129,084 | ||
| 2021-03-17 | JANTZ DEREK Chief Scientific Officer | Option exercise | +21,514 | $0.04 | $861 | 3,979,060 |
| 2021-03-17 | JANTZ DEREK Chief Scientific Officer | Sale | −9,665 | $10.92 | $106K | 3,969,395 |
| 2021-03-17 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 150,598 | ||
| 2021-03-16 | JANTZ DEREK Chief Scientific Officer | Option exercise | +21,514 | $0.04 | $861 | 3,967,207 |
| 2021-03-16 | JANTZ DEREK Chief Scientific Officer | Sale | −9,661 | $11.97 | $116K | 3,957,546 |
| 2021-03-16 | JANTZ DEREK Chief Scientific Officer | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 172,112 | ||
| 2021-03-12 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 1,939,180 |
| 2021-03-12 | KANE MATTHEW R. President and CEO | Sale | −9,712 | $11.36 | $110K | 1,929,468 |
| 2021-03-12 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 129,084 | ||
| 2021-03-11 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 1,927,377 |
| 2021-03-11 | KANE MATTHEW R. President and CEO | Sale | −9,711 | $11.38 | $111K | 1,917,666 |
| 2021-03-11 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 150,598 | ||
| 2021-03-10 | KANE MATTHEW R. President and CEO | Option exercise | +21,514 | $0.04 | $861 | 1,915,573 |
| 2021-03-10 | KANE MATTHEW R. President and CEO | Sale | −9,710 | $11.79 | $114K | 1,905,863 |
| 2021-03-10 | KANE MATTHEW R. President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −21,514 | 172,112 |
Page 22 of 23 · 456 trades